Search Results
Results found for "Inversago Pharma"
Posts (347)
- Inversago Pharma appoints Glenn S. Vraniak as Chief Financial Officer
May 2022 "MONTREAL (CANADA) – May 17, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today Before joining Inversago, Mr.
- Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B ...
March 2022 Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B Clinical Trial "MONTREAL (CANADA) – March 15, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announced This 28-day trial will test the pharmacokinetics and safety profile of Inversago’s lead molecule, INV
- Inversago Pharma Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker and...
January 2022 Inversago Pharma Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker Phase 2 clinical development Metabolic disorders are a global epidemic1 MONTREAL--(BUSINESS WIRE)--Inversago Pharma Inc. (“Inversago”), the peripheral CB1 blockade company, announced today the successful completion of the Favorable safety, tolerability and pharmacokinetic results from the trial warrant further investigation
Other Pages (220)
- Team Access to Terry’s Pharmacology Corner | 25% Group Discount | Dr. GPCR Ecosystem
Equip your research team with expert-led GPCR pharmacology training. Used by discovery scientists across biotech, pharma, and academia. Shared pharmacology discipline for discovery teams. Corner lessons and analysis • Ability to suggest topics relevant to your programs • Access for biotech, pharma Expert-Level Mastery — Advanced Pharmacology Live AMA Sessions with Terry
- how-to-build-breakthrough-gpcr-programs | Dr. GPCR Ecosystem
Andrew Tobin draws from his experience leading translational GPCR programs and co-founding Keltic Pharma As co-founder and CEO of Keltic Pharma Therapeutics, he leads a biotechnology company developing a novel
- GPCR Assay Strategy, Bias, and Translational Drug Discovery | Dr. GPCR Ecosystem
Explore Martin Marro’s impact on GPCR drug discovery, assay innovation, and translational pharmacology bridging academia, pharma, and biotech. << Back to podcast list Strategic Partner(s) GPCR Assay Strategy Martin Marro, currently Executive Director and Head of Cell Pharmacology at Eli Lilly’s Obesity Research Marro’s career spans big pharma and biotech, encompassing functional assay development, GPCR internalization Scientists seeking practical advice on career pivots between academia, pharma, and biotech.
